Life sciences enterprises are moving beyond siloed, function-specific platforms toward AI-native, interoperable ecosystems that connect workflows across R&D, clinical development, manufacturing, regulatory, commercial, and enterprise operations.
The Life Sciences Partner Ecosystem Report 2026 examines how technology platform ecosystems are structured and adopted, and how they are evolving across pharma, biopharma, medtech, biotechnology, clinical research, and healthcare technology organizations.
Life sciences enterprises are increasingly building platform-based operating models that connect core functions across the value chain. As these platforms mature, the focus is shifting toward AI-enabled workflows, interoperable data architectures, outcome-linked partnerships, and stronger governance for GxP validation, data integrity, AI risk, and cross-border compliance.
The Life Sciences Partner Ecosystem Report 2026 analyzes platform adoption across R&D/drug discovery, preclinical and clinical trials, manufacturing, procurement and supply chain, sales and marketing, patient support and pharmacovigilance, regulatory, and enterprise operations.
The report is grounded in Avasant Research’s RadarView assessments of over 35 service providers and more than 150 technology partners, supported by market tracking, surveys, and public disclosures such as annual reports and earnings calls. Insights are further informed by direct engagement with enterprise executives and platform vendor leaders.
The report identifies four structural shifts shaping the life sciences partner ecosystem:
Together, these shifts show how life sciences organizations are redesigning partner strategies around interoperability, governance, compliance, accountability, and measurable business outcomes.
The report maps more than 100 identified partners across eight life sciences partner categories, including AI-enabled drug discovery, clinical trial platforms, digital manufacturing, procurement and supply chain platforms, commercial engagement platforms, pharmacovigilance platforms, regulatory platforms, cloud, cybersecurity, data governance, and enterprise operations platforms.
A key finding highlights that multipartner life sciences ecosystems create new enterprise risks, including validation accountability gaps, platform lock-in, cross-platform data integrity risk, AI governance gaps, and data sovereignty challenges. These risks are becoming more prominent as organizations scale AI-enabled workflows across regulated functions.
The report also highlights the growing role of Veeva and Salesforce as foundational ecosystem platforms, while cloud, data, AI, regulatory, pharmacovigilance, and commercial engagement platforms increasingly converge to support more connected life sciences operating models.
“Life sciences enterprises are entering a new phase of platform-led transformation, where ecosystem success depends on interoperability, governance, and the ability to scale AI responsibly across regulated workflows,” said Eratha Poongkuntran, associate director at Avasant.
The Life Sciences Partner Ecosystem Report 2026 provides biopharma enterprises, medtech organizations, technology vendors, service providers, and life sciences leaders with a structured view of partner category maturity, platform adoption trends, value propositions, operating-model roles, and ecosystem risks across the life sciences value chain.
Avasant’s research and other publications are based on information from the best available sources and Avasant’s independent assessment and analysis at the time of publication. Avasant takes no responsibility and assumes no liability for any error/omission or the accuracy of information contained in its research publications. Avasant does not endorse any provider, product or service described in its RadarView™ publications or any other research publications that it makes available to its users, and does not advise users to select only those providers recognized in these publications. Avasant disclaims all warranties, expressed or implied, including any warranties of merchantability or fitness for a particular purpose. None of the graphics, descriptions, research, excerpts, samples or any other content provided in the report(s) or any of its research publications may be reprinted, reproduced, redistributed or used for any external commercial purpose without prior permission from Avasant, LLC. All rights are reserved by Avasant, LLC.
Login to get free content each month and build your personal library at Avasant.com
